Oct 2026· The Oncologist· Vol 31· 0 citations· 36 references
Medicine
TL;DR
Real-world outcomes among NATALEE and monarchE-eligible patients are consistent with results from phase III trial comparator arms, and both NATALEE and monarchE eligibility were associated with distant metastasis, and mortality.
Abstract
Abstract Background Adjuvant cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have improved outcomes in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) early breast cancer (eBC) in the NATALEE and monarchE trials. However, real‑world evidence on the proportion of candidates for adjuvant CDK4/6 inhibitors and their outcomes within these trial-defined populations remains limited. Materials and Methods We conducted a retrospective, population‑based cohort study including all patients diagnosed with HR+/HER2– eBC in the Hospital District of Helsinki and Uusimaa, Finland, between January 2014 and June 2023. Patients were classified according to NATALEE and/or monarchE eligibility criteria. Outcomes assessed were invasive disease‑free survival (iDFS), distant disease‑free survival (DDFS), and overall survival (OS). Results Among 8911 patients with HR+/HER2- eBC and a median follow-up of 5.2 years, 40.4% met the NATALEE eligibility criteria and 15.0% met the monarchE criteria. Eligible patients were younger and had higher‑grade tumors and greater proliferation rate than non-eligible patients. Five‑year outcomes were consistently worse in eligible than ineligible patients (NATALEE: iDFS 82.5% vs 89.6%, DDFS 88.3% vs 94.5%, OS 90.9% vs 95.6%; monarchE: iDFS 76.8% vs 88.4%, DDFS 82.3% vs 93.8%, OS 86.8% vs 94.9%). Metastatic progression occurred 3‑ to 6‑fold more often in eligible patients. In multivariable models, both NATALEE and monarchE eligibility were associated with distant metastasis, and mortality. Conclusion Real-world outcomes among NATALEE and monarchE-eligible patients are consistent with results from phase III trial comparator arms. Trial‑defined eligibility criteria reliably identify patients with substantially poorer prognosis, supporting risk‑adapted adjuvant strategies and the integration of CDK4/6 inhibitors into clinical practice.
The findings provide real-world historical outcome data for patients who would now be considered candidates for adjuvant ribociclib and may serve as a benchmark for evaluating outcomes following adoption of adjuvant ribociclib.
H. Abdel-Razeq, M. Horani, F. Tamimi et al.· Drug Design, Development and...· 0 citations
Positive OS results with a clinically relevant benefit of ribociclib plus NSAI are demonstrated, consistent with the increasing reduction in recurrence risk, and reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.
D. Slamon, G. Hortobagyi, D. Stroyakovskiy et al.· Annals of Oncology· 1 citation
BACKGROUND
Everolimus-based endocrine therapy is used for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) metastatic breast cancer after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment, but factors associated with treatment durability remain unclear. We...
Hikari Kiyohara, Toru Hanamura, Y. Sagara et al.· Breast Cancer· 0 citations
This retrospective study shows heterogeneity in treatment patterns and survival outcomes in real-world patients with HER2-positive mBC, indicating the need for optimization of treatment in patients with HER2-positive mBC in real-world.
S. C. Lee, C. Barrios, W. Chung et al.· ESMO Open· 0 citations
Introduction: Tumor-infiltrating lymphocytes (TILs) are established prognostic and predictive biomarkers in early-stage triple-negative breast cancer (eTNBC). The addition of pembrolizumab to neoadjuvant chemotherapy (NAC) improves outcomes, as demonstrated in the KEYNOTE-522 trial. The role of TILs in this setting war...
R. Bonadio, M. Monteiro, W. Lima et al.· Mastology· 0 citations
The findings reinforce the high unmet need in patients with HR+/HER2’s metastatic breast cancer whose disease has become resistant to ET, highlighting the need for effective treatments in this setting.
J. O'Shaughnessy, M. Rehnquist, N. Sadetsky et al.· Breast Cancer Research and T...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.